DUBLIN--(BUSINESS WIRE)--The "Spiriva" report has been added to ResearchAndMarkets.com's offering. Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for ...

INGELHEIM AM RHEIN, Germany & NEW YORK, N.Y., USA--(BUSINESS WIRE)--Results of the one-year Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD ®) study, published today by the New England ...

March 19, 2008 — The US Food and Drug Administration (FDA) is reporting a possible increased risk of stroke with use of tiotropium (Spiriva HandiHaler, Boehringer Ingelheim Pharmaceuticals, Inc), ...

LONDON, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (VRP.L) (VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies ...

Boehringer Ingelheim today announced that the indication for Spiriva ® (tiotropium) Respimat ®* in asthma has been accepted by the regulatory authorities in the EU. Spiriva ® Respimat ® is indicated ...

RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee ...

RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term ...

SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated ...

RIDGEFIELD, Conn., August 19, 2014 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose ...

Post hoc analyses of some Phase 3 placebo-controlled studies showed that adding Spiriva Respimat improved peak FEV1(0-3h) and trough FEV1 across a range of baseline IgE levels and eosinophil counts.

Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and ...